Skip to main content
LYPHF logo

Luye Pharma Group Ltd. (LYPHF) Stock Price & Analysis

Luye Pharma Group Ltd. (LYPHF) — price $0.27 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.08B.

Educational signal · not a buy or sell recommendation · How to read this

$0.27 $0.00 (0.00%) Market Cap $1.08B

Luye Pharma Group Ltd. · LYPHF

Luye Pharma Group Ltd. is a global pharmaceutical company engaged in the development, production, marketing, and sale of a diverse range of pharmaceutical and biopharmaceutical products. Its portfolio addresses critical therapeutic areas including oncology, central nervous system disorders, pain management, and metabolic diseases.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • CRON · Cronos Group Inc. · 95 /100
  • HROW · Harrow Health, Inc. · 33 /100
  • AMPH · Amphastar Pharmaceuticals, Inc. · 86 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.27
Change on the day0.00%
Market capitalisation$1.08B
Price / earnings (trailing)7.39
Shares traded on the day2.5K

Price & events

Other perspectives

Council score for Luye Pharma Group (LYPHF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Sep 6, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Weak
Debt/Equity Negative
ROE Weak
Gross Margin Strong

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Luye Pharma Group (LYPHF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Luye Pharma Group Ltd. (LYPHF) is the company analyzed here. It employs 5,270 people. In Q2 FY2026 it reported revenue of CN¥2.96B and net income of CN¥385M. The market values it at $1.08B.

2 · Latest results

What do the latest results show for Luye Pharma Group (LYPHF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CN¥2.96B. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CN¥2.96BCN¥385MCN¥0.10 (diluted)
Q4 FY2025CN¥3.08BCN¥301MCN¥0.07 (diluted)
Q2 FY2025CN¥3.18BCN¥313MCN¥0.08 (diluted)
Q4 FY2024CN¥2.99BCN¥84MCN¥0.02 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Luye Pharma Group (LYPHF)?

Short answer · as of

The distress and quality screens read Altman Z 1.04 · Piotroski F 6. Trailing ratios: ROE 4.4% · ROA 2.0% · current ratio 1.45 · earnings yield 13.1% · free-cash-flow yield 19.4%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LYPHF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LYPHF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Luye Pharma Group (LYPHF)

These answers are editorial: 1 of these 8 answers is drawn from the LYPHF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is LYPHF a good stock to buy?

Stock Expert AI does not rate LYPHF buy, sell or hold. Luye Pharma Group Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the LYPHF stock price today?

The last price recorded for Luye Pharma Group Ltd. (LYPHF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Luye Pharma Group Ltd. do?

Luye Pharma Group Ltd. is an investment holding company that globally develops, produces, markets, and sells a wide array of pharmaceutical and biopharmaceutical products.

What are the key factors to evaluate for LYPHF?

Evaluate LYPHF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Expansion in Oncology Therapeutics: Luye Pharma maintains a robust oncology portfolio, including treatments like Lipusu for ovarian and breast cancer, Tiandida for lung cancer, and Boyounuo for various solid tumors. Not financial advice.

How frequently does LYPHF data refresh on this page?

LYPHF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven LYPHF's recent stock price performance?

Luye Pharma Group Ltd. (LYPHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive and diversified product portfolio across multiple therapeutic areas (oncology, CNS, pain, metabolic). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LYPHF overvalued or undervalued right now?

The trailing P/E of Luye Pharma Group Ltd. (LYPHF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research LYPHF before investing?

Before investing in Luye Pharma Group Ltd. (LYPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 10 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.